Literature DB >> 6380349

Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.

D M Aviado, H R Dettelbach.   

Abstract

Physiological and pathophysiological aspects of systemic and cardiac haemodynamics are reviewed with appraisal of Carl J. Wiggers merits and contributions to the research and developments in this field and his early recognition of the significance of the flow properties of blood in impaired circulation. Pharmacological agents involved in treatment of peripheral vascular diseases are discussed with special regard to the haemorheologically active xanthine derivative pentoxifylline. The profile of pentoxifylline as it emerges from experimental pharmacological and clinical studies is presented paying special attention to the haemorheological properties of the drug. Pharmacokinetic features of pentoxifylline are surveyed touching absorption, blood levels, metabolism and excretion aspects. Basing on the available data pentoxifylline is regarded as a promising drug in the treatment of circulatory ischemic disorders, especially in intermittent claudication.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6380349     DOI: 10.1177/000331978403500703

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  9 in total

1.  Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.

Authors:  D J Stewart; R Goel; M C Cripps; S Huan; J Yau; S Verma
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard.

Authors:  B Poon; J B Jowett; S A Stewart; R W Armstrong; G M Rishton; I S Chen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas.

Authors:  D J Stewart; S Dahrouge; O Agboola; A Girard
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

Review 4.  Pentoxifylline in preterm neonates: a systematic review.

Authors:  Emma Harris; Sven M Schulzke; Sanjay K Patole
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

Review 5.  Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?

Authors:  Shelly Bhanot; David J Leehey
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

6.  Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.

Authors:  K S Smith; B A Folz; E G Adams; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Impact of different antithrombotics on the microcirculation and viability of perforator-based ischaemic skin flaps in a small animal model.

Authors:  Andreas M Fichter; Lucas M Ritschl; Luisa K Robitzky; Stefan Wagenpfeil; David A Mitchell; Klaus-Dietrich Wolff; Thomas Mücke
Journal:  Sci Rep       Date:  2016-10-21       Impact factor: 4.379

8.  Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.

Authors:  Martha E Cancino-Marentes; Georgina Hernández-Flores; Pablo Cesar Ortiz-Lazareno; María Martha Villaseñor-García; Eduardo Orozco-Alonso; Erick Sierra-Díaz; Raúl Antonio Solís-Martínez; Claudia Carolina Cruz-Gálvez; Alejandro Bravo-Cuellar
Journal:  BMC Urol       Date:  2021-03-12       Impact factor: 2.264

Review 9.  Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target.

Authors:  Jiahao Chen; Qinhui Liu; Jinhan He; Yanping Li
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.